2013, Volkow et al., 2013), and administration of Naltrexone, an opioid antagonist approved by the U.S. Food and Drug Administration for the treatment of AUD (Kranzler and Soyka, 2018), has been shown to reduce the frequency of binge-eating episodes among individuals with an eating disorder (Jonas and Gold, 1988, Stancil et al., in press). Thus, our findings highlight the importance of expanding GWAS to include BN and binge-eating disorder, where a core symptom of both disorders is binge eating, to elucidate whether binge eating is a critical eating disorder symptom in the comorbidity with AUD and to home in on the relevant shared mechanisms.
